Von E. needs a plan B
This article was originally published in The Tan Sheet
Executive Summary
A Senate Health Committee staffer believes it is "highly unlikely" that acting FDA Commissioner Andrew von Eschenbach will be confirmed this year. Sens. Hillary Clinton (D-N.Y.) and Patty Murray (D-Wash.) placed a hold on von Eschenbach's confirmation due to the agency's failure to provide a timeline for a decision on the over-the-counter switch application for Barr's emergency contraceptive Plan B (1"The Tan Sheet" April 3, 2006, p. 4)...
You may also be interested in...
Plan B Backlash Blocks FDA Commissioner Nomination: Take Two
FDA will not have a permanent commissioner until an actual decision is announced on the proposed Rx to-OTC switch of emergency contraceptive Plan B, if a hold by Senate Democrats is respected
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.